U.S. Markets close in 6 hrs 7 mins

Allakos Inc. (ALLK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
85.13-1.37 (-1.58%)
As of 9:51AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close86.50
Open87.59
Bid84.79 x 1100
Ask85.49 x 800
Day's Range84.85 - 87.59
52 Week Range41.61 - 139.99
Volume20,794
Avg. Volume308,735
Market Cap4.151B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.36
Earnings DateAug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est82.00
  • GlobeNewswire

    Allakos Reports Second Quarter 2020 Financial Results and Provides Business Update

    REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the second quarter ended June 30, 2020 and provided an update of its ongoing development activities. Business Updates * Patient enrollment was initiated in a randomized, double-blind, placebo-controlled Phase 3 study of AK002 in patients with eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD). Topline data are expected in the second half of 2021. * Patient enrollment was initiated in a randomized, double-blind, placebo-controlled Phase 2/3 study of AK002 in patients with eosinophilic esophagitis (EoE). Topline data are expected in the second half of 2021. * The Phase 1 safety, tolerability and pharmacokinetics study of the subcutaneous formulation of AK002 is fully enrolled. Results are expected in the second half of 2020. * The non-interventional study examining the prevalence of EG, EoD, and mast cell gastrointestinal disease (MGID) in patients with chronic functional gastrointestinal disease is fully enrolled. Results are expected in the second half of 2020. * Announced positive clinical safety and efficacy results from a six-month, open-label Phase 1 study of AK002 in patients with MGID in March 2020. * Announced positive interim safety and efficacy results from the open-label, long-term extension component of the ENIGMA study with AK002 in patients with EG and/or EoD. The results were accepted for oral presentation and presented virtually at the Digestive Disease Week (DDW) Annual Meeting in May 2020. * The nonproprietary (generic) name of AK002 was changed from antolimab to lirentelimab as a result of trademark issues identified outside of the United States. Lirentelimab has been adopted by the United States Adopted Names (USAN) Council and World Health Organization (WHO) International Nonproprietary Names (INN) Program.Second Quarter 2020 Financial ResultsResearch and development expenses were $28.3 million in the second quarter of 2020 as compared to $14.1 million in the same period in 2019, an increase of $14.2 million.General and administrative expenses were $12.1 million in the second quarter of 2020 as compared to $5.9 million in the same period in 2019, an increase of $6.2 million.Allakos reported a net loss of $39.3 million in the second quarter of 2020 as compared to $19.1 million in the same period in 2019, an increase of $20.2 million. Net loss per basic and diluted share was $0.80 for the second quarter of 2020 compared to $0.44 in the same period in 2019.Allakos ended the second quarter of 2020 with $454.9 million in cash, cash equivalents and marketable securities.About Allakos Allakos is a clinical-stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE). Lirentelimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Lirentelimab has been tested in multiple clinical studies, in which lirentelimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with eosinophilic gastritis and/or eosinophilic duodenitis, eosinophilic esophagitis, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria and indolent systemic mastocytosis. For more information, please visit the Company's website at www.allakos.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, Allakos’ progress and business plans. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to: Allakos’ early stages of clinical drug development; Allakos’ ability to timely complete clinical trials for, and if approved, commercialize lirentelimab (AK002), its lead compound; Allakos’ ability to obtain required regulatory approvals for its product candidates; uncertainties related to the enrollment of patients in its clinical trials; Allakos’ ability to demonstrate sufficient safety and efficacy of its product candidates in its clinical trials; uncertainties related to the success of later-stage clinical trials, regardless of the outcomes of preclinical testing and early-stage trials; market acceptance of Allakos’ product candidates; uncertainties related to the projections of the size of patient populations suffering from the diseases Allakos is targeting; Allakos’ ability to advance additional product candidates beyond lirentelimab (AK002); Allakos’ ability to obtain additional capital to finance its operations; and other important risk factors set forth in Allakos’ most recent Annual Report on Form 10-K filed with the SEC on February 25, 2020, Quarterly Report on Form 10-Q filed with the SEC on August 10, 2020 and future reports to be filed with the SEC. These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos’ forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Allakos specifically disclaims any obligation to update any forward-looking statement, except as required by law. These forward-looking statements should not be relied upon as representing Allakos’ views as of any date subsequent to the date of this press release.Source: Allakos Inc. ALLAKOS INC. STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except per share data) (unaudited)  Three Months Ended  Six Months Ended    June 30,  June 30,    2020  2019  2020  2019  Operating expenses                 Research and development $28,346  $14,111  $46,631  $29,209  General and administrative  12,058   5,946   23,646   11,775  Total operating expenses  40,404   20,057   70,277   40,984  Loss from operations  (40,404)  (20,057)  (70,277)  (40,984) Interest income, net  1,284   971   3,273   2,001  Other income (expense), net  (172)  14   (112)  (42) Net loss  (39,292)  (19,072)  (67,116)  (39,025) Unrealized gain (loss) on marketable securities, net of tax  (1,219)  84   650   129  Comprehensive loss $(40,511) $(18,988) $(66,466) $(38,896) Net loss per common share:                 Basic and diluted $(0.80) $(0.44) $(1.38) $(0.91) Weighted-average number of common shares outstanding:                 Basic and diluted  48,816   43,115   48,753   42,868  ALLAKOS INC. CONDENSED BALANCE SHEETS (in thousands)   June 30,  December 31,    2020  2019    (unaudited)      Assets         Current assets:         Cash and cash equivalents $153,898  $38,367  Investments in marketable securities  301,048   457,534  Prepaid expenses and other current assets  3,336   3,969  Total current assets  458,282   499,870  Property and equipment, net  7,703   8,410  Operating lease right-of-use assets  5,633   5,775  Other long-term assets  2,839   2,839  Total assets $474,457  $516,894  Liabilities and stockholders' equity         Current liabilities:         Accounts payable $9,617  $5,963  Accrued expenses and other current liabilities  9,962   7,098  Total current liabilities  19,579   13,061  Other long-term liabilities  7,875   8,112  Total liabilities  27,454   21,173  Stockholders' equity:         Common stock  49   48  Additional paid-in capital  702,767   685,020  Accumulated other comprehensive gain  787   137  Accumulated deficit  (256,600)  (189,484) Total stockholders’ equity  447,003   495,721  Total liabilities and stockholders’ equity $474,457  $516,894  CONTACT: Investor Contact: Adam Tomasi, President and COO ir@allakos.com Media Contact: Denise Powell denise@redhousecomms.com

  • Companies Like Allakos (NASDAQ:ALLK) Can Afford To Invest In Growth
    Simply Wall St.

    Companies Like Allakos (NASDAQ:ALLK) Can Afford To Invest In Growth

    We can readily understand why investors are attracted to unprofitable companies. For example, Allakos (NASDAQ:ALLK...

  • Hedge Funds Dropped The Ball On Allakos Inc. (ALLK)
    Insider Monkey

    Hedge Funds Dropped The Ball On Allakos Inc. (ALLK)

    The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]